These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 10227593)

  • 41. Determination of features indicating progression in atypical squamous cells with undetermined significance: human papillomavirus typing and DNA ploidy analysis from liquid-based cytologic samples.
    Bollmann R; Méhes G; Torka R; Speich N; Schmitt C; Bollmann M
    Cancer; 2003 Apr; 99(2):113-7. PubMed ID: 12704691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by Hybrid Capture II and polymerase chain reaction.
    Riethmuller D; Gay C; Bertrand X; Bettinger D; Schaal JP; Carbillet JP; Lassabe C; Arveux P; Seilles E; Mougin C
    Diagn Mol Pathol; 1999 Sep; 8(3):157-64. PubMed ID: 10565688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HPV testing with cytology triage for cervical cancer screening in routine practice.
    Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
    Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.
    Salmerón J; Lazcano-Ponce E; Lorincz A; Hernández M; Hernández P; Leyva A; Uribe M; Manzanares H; Antunez A; Carmona E; Ronnett BM; Sherman ME; Bishai D; Ferris D; Flores Y; Yunes E; Shah KV
    Cancer Causes Control; 2003 Aug; 14(6):505-12. PubMed ID: 12948281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.
    Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Woodward L
    J Fam Pract; 1998 Feb; 46(2):136-41. PubMed ID: 9487319
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of CellSolutions BestPrep® automated thin-layer liquid-based cytology Papanicolaou slide preparation and BestCyte® cell sorter imaging system.
    Delga A; Goffin F; Kridelka F; Marée R; Lambert C; Delvenne P
    Acta Cytol; 2014; 58(5):469-77. PubMed ID: 25277345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.
    Costa S; Sideri M; Syrjänen K; Terzano P; De Nuzzo M; De Simone P; Cristiani P; Finarelli AC; Bovicelli A; Zamparelli A; Bovicelli L
    Acta Cytol; 2000; 44(3):310-8. PubMed ID: 10833984
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Liquid-based cervical cytology ThinPrep screening in Hungary].
    Bak M; Séberné Éll M; Bóka M; Veleczki Z; Nyári T; Pete I; Szentirmay Z
    Orv Hetil; 2014 May; 155(18):708-14. PubMed ID: 24776385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears.
    Shlay JC; Dunn T; Byers T; Barón AE; Douglas JM
    Obstet Gynecol; 2000 Sep; 96(3):410-6. PubMed ID: 10960635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colposcopy, cytology and histology in the diagnosis of squamous intraepithelial lesions of the cervix.
    Carta G; Di Stefano L; Catellani Perelli A; Toro G; Moscarini M
    Clin Exp Obstet Gynecol; 1999; 26(2):60-6. PubMed ID: 10459438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?
    Miranda Pereira SM; Castelo A; Makabe S; Utagawa ML; Di Loreto C; Sakamoto Maeda MY; Marques JA; Santoro CL; Filho AL; Das Dores GB
    Int J Gynecol Pathol; 2006 Jan; 25(1):38-41. PubMed ID: 16306782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology.
    de Cremoux P; Coste J; Sastre-Garau X; Thioux M; Bouillac C; Labbé S; Cartier I; Ziol M; Dosda A; Le Galès C; Molinié V; Vacher-Lavenu MC; Cochand-Priollet B; Vielh P; Magdelénat H;
    Am J Clin Pathol; 2003 Oct; 120(4):492-9. PubMed ID: 14560561
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening.
    Coste J; Cochand-Priollet B; de Cremoux P; Le Galès C; Cartier I; Molinié V; Labbé S; Vacher-Lavenu MC; Vielh P;
    BMJ; 2003 Apr; 326(7392):733. PubMed ID: 12676841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-risk human papillomavirus deoxyribonucleic acid as an adjunct marker in cervical cytology.
    Lin CT; Tseng CJ; Chou HH; Huang KG; Chang TC; Lai HH; Soong YK
    Changgeng Yi Xue Za Zhi; 1999 Sep; 22(3):409-15. PubMed ID: 10584412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation.
    Lytwyn A; Sellors JW; Mahony JB; Daya D; Chapman W; Howard M; Roth P; Lorincz AT; Gafni A; Walter SD
    Arch Pathol Lab Med; 2003 Sep; 127(9):1169-75. PubMed ID: 12946228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology.
    Longatto-Filho A; Naud P; Derchain SF; Roteli-Martins C; Tatti S; Hammes LS; Sarian LO; Eržen M; Branca M; de Matos JC; Gontijo R; Maeda MY; Lima T; Costa S; Syrjänen S; Syrjänen K
    Virchows Arch; 2012 Jun; 460(6):577-85. PubMed ID: 22562132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.
    Wang SS; Trunk M; Schiffman M; Herrero R; Sherman ME; Burk RD; Hildesheim A; Bratti MC; Wright T; Rodriguez AC; Chen S; Reichert A; von Knebel Doeberitz C; Ridder R; von Knebel Doeberitz M
    Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1355-60. PubMed ID: 15298958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.